Purity ≥ 99%Tirzepatide Dual GIP/GLP-1 agonist
- Synthetic peptide
- ≥99% purity
- CoA per lot
Analytical-grade peptide reference material, supplied as a lyophilized powder for in-vitro laboratory research use only.
Bundle and bulk savings, codes and shipping are worked out in the cart at VNG.
Free shipping over $149 · CoA included with every order
What it is
A single-molecule dual agonist of the GIP and GLP-1 receptors, studied in metabolic and body-composition research as a successor to GLP-1-only compounds.
How it is studied
By activating both incretin receptors at once, it is investigated for combined effects on appetite signaling, insulin response, and energy metabolism.
Research areas
Metabolic regulation, glycemic and body-composition research.
Lab report for every lot
Each lot ships with a Certificate of Analysis matched to its lot number: purity, identity, heavy metals, sterility and endotoxin.
Published research
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trialLancet (London, England), 2021
- Tirzepatide as compared with semaglutide for the treatment of obesityThe New England journal of medicine, 2025
- Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosisThe New England journal of medicine, 2024
- Tirzepatide reduces appetite, energy intake, and fat mass in people with type 2 diabetesDiabetes care, 2023
- Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonistJCI insight, 2020
- Tirzepatide: a review in type 2 diabetesDrugs, 2024
Research use only. Not for human or animal consumption. Not evaluated by the FDA. Not intended to diagnose, treat, cure, or prevent any disease.
